Skip to main content
Earnings Labs
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT)

NASDAQ·Healthcare·Biotechnology

$1.68

+0.60%

Mkt Cap $137.04M

Analyst Ratings

No recent rating data.

Price Target (3 analysts)

$4.00

Range $4.00$4.00

Implied Upside

+138.1%

Consensus $4.00 vs current $1.68